

## **ISTAART Immersives: Mastering Fluid Biomarkers to Unlock the Secrets of Alzheimer's Disease and Related Dementias**

Friday, July 10, 2026 | 8 a.m. - 5 p.m.

Peninsula East — InterContinental — London, United Kingdom

All times are in British Summer Time

*In-person attendance only*

### **Overview**

The Basics of Fluid Biomarkers in Alzheimer's Disease is organized by leading scientists in this field from the ISTAART Biofluid Based Biomarker PIA and by the Alzheimer's Association Global Biomarkers Standardization Consortium (GBSC). The fluid biomarkers field for Alzheimer's disease (AD), and other dementias is rapidly expanding. This workshop aims to provide participants with an in-depth understanding of the fundamental principles, differences in methodology, and clinical and research applications of AD biomarkers present in cerebrospinal fluid (CSF) and blood. This workshop will include fundamental laboratory-focused sessions that capture the advances in neurochemistry, sample handling, assay methods and development, quality control, and regulatory considerations. It will also incorporate clinical practice-focused sessions that cover considerations for AD fluid biomarker implementation, the context of use, disclosure, and the gaps and opportunities in this field. These sessions will cover both standard AD biomarkers and emerging biomarkers and novel platforms in development. Lectures will include interactive poll questions within presentations followed by Q&A sessions and discussions to ensure that participants understand the current and future state of fluid biomarkers.

### **Organizing Committee**

- Nicholas Ashton, PhD
- Laia Montoliu-Gaya, PhD
- Alicia Algeciras-Schimnich, PhD
- Ashvini Keshavan, PhD
- Jeff Dage, PhD
- Charlotte Teunissen, PhD

### **Target Audience**

This ISTAART immersive workshop is designed for researchers at the intermediate and advanced levels.

## Learning Objectives

- Provide an in-depth understanding of the fundamental principles, inherent limitations, and clinical and research applications of the most common biomarkers used in AD and found in CSF and blood.
- Provide an overview about the status of the field of biofluid based biomarkers for other causes of dementia (non-AD dementia).
- Provide the basics of neurochemistry, technical issues of sample collection, storage, analysis methods, quality control, and regulatory issues.
- Cover the latest in cutting-edge biomarker technology, including blood-based biomarkers, with the current understanding of how biomarkers track the progression in AD and their use in other dementias.

## Registration

Pre-conferences are offered for in-person attendance only. Preconferences require a separate registration fee in addition to AAIC full conference registration, or they may be purchased as stand-alone events. Visit [alz.org/AAIC](http://alz.org/AAIC).

## Agenda: Friday, July 10, 2026 | 8 a.m. - 5 p.m.

Time	Session Details	Speakers and Moderator
8:20-8:40 AM	Overview of Core CSF Alzheimer's Disease Biomarkers	Henrik Zetterberg
8:45-9:05 AM	Overview of Core Blood Based Alzheimer's Disease Biomarkers	Nicholas Ashton
9:10-9:30 AM	5 Things to know: CSF and Blood Biomarkers and Analytics Overview	Inge Verberk
9:35-9:45 AM	Q&A	
9:50-10:10 AM	Break	
<b>Session 2: Alzheimer's disease and related dementias biomarker discovery</b>		
10:15-10:35 AM	Introduction to Multi-Analyte Panels	Frederica Anastasi

10:40-11:00 AM	Large Immunoassay Based Biomarker Panels for Biomarker Discovery	Charlotte Teunissen
11:05-11:25 AM	Large Aptamer Based Panels for Biomarker Discovery	Carlos Cruchaga
11:30 AM-12:00 PM	Discussion and Poll Question	
12:05-1:05 PM	Lunch	
<b>Session 3: Translational Considerations of CSF and Plasma Biomarkers</b>		
1:05-1:25 PM	Practical Considerations for Clinical Implementation of Blood Biomarkers	Alicia Algeciras-Schimmich
1:30-1:50 PM	Effects of Sociodemographics and Multiple Chronic Conditions on Biomarkers	Michelle Mielke
1:55-2:15 PM	Using Biofluid Markers for Clinical Trial Enrichment and Pharmacodynamics	Jeff Dage
2:20-2:35 PM	Q&A	
2:35-2:55 PM	Break	
<b>Session 4: Clinical – Case Based Approaches</b>		
3:00-3:30 PM	Appropriate Use Recommendations and Context of Use for CSF Biomarkers for Alzheimer's Disease and Other Dementia (Case-Based Approach)	Jonathan Schott
3:35-4:05 PM	Appropriate Use Recommendations and Context of Use for Blood Biomarkers for Alzheimer's Disease (Case-Based Approach)	Suzanne Schindler

4:05-4:30 PM	Discussion and Poll Question	
	Workshop Survey	